tezepelumab (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

Asthma

Pending FDA approval to prevent exacerbation of severe asthma in adults and adolescents

Next:

Pharmacology

Mechanism of Action

Monoclonal antibody that inhibits thymic stromal lymphopoietin (TSLP), a key epithelial cytokine involved in multiple inflammatory cascades and initiates an over reactive immune response to allergic, eosinophilic, and other types of airway inflammation associated with severe asthma

TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses and other airborne particles; expression of TSLP is increased in the airways of patients with asthma and has been correlated with disease severity

Blocking TSLP may prevent the release of proinflammatory cytokines by immune cells, resulting in prevention of asthma exacerbations and improved asthma control

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.